Kawada Kenji, Sonoshita Masahiro, Sakashita Hiromi, Takabayashi Arimichi, Yamaoka Yoshio, Manabe Toshiaki, Inaba Kayo, Minato Nagahiro, Oshima Masanobu, Taketo Makoto Mark
Department of Pharmacology, Graduate School of Medicine, Kyoto University, Kyoto.
Cancer Res. 2004 Jun 1;64(11):4010-7. doi: 10.1158/0008-5472.CAN-03-1757.
Chemokines and their receptors play key roles in leukocyte trafficking and are also implicated in cancer metastasis to specific organs. Here we show that mouse B16F10 melanoma cells constitutively express chemokine receptor CXCR3, and that its ligands CXCL9/Mig, CXCL10/IP-10, and CXCL11/I-TAC induce cellular responses in vitro, such as actin polymerization, migration, invasion, and cell survival. To determine whether CXCR3 could play a role in metastasis to lymph nodes (LNs), we constructed B16F10 cells with reduced CXCR3 expression by antisense RNA and investigated their metastatic activities after s.c. inoculations to syngeneic hosts, C57BL/6 mice. The metastatic frequency of these cells to LNs was markedly reduced to approximately 15% (P < 0.05) compared with the parental or empty vector-transduced cells. On the other hand, pretreatment of mice with complete Freund's adjuvant increased the levels of CXCL9 and CXCL10 in the draining LNs, which caused 2.5-3.0-fold increase (P < 0.05) in the metastatic frequency of B16F10 cells to the nodes with much larger foci. Importantly, such a stimulation of metastasis was largely suppressed when CXCR3 expression in B16F10 cells was reduced by antisense RNA or when mice were treated with specific antibodies against CXCL9 and CXCL10. We also demonstrate that CXCR3 is expressed on several human melanoma cell lines as well as primary human melanoma tissues (5 of 9 samples tested). These results suggest that CXCR3 inhibitors may be promising therapeutic agents for treatment of LN metastasis, including that of melanoma.
趋化因子及其受体在白细胞迁移中起关键作用,并且也与癌症转移至特定器官有关。在此我们表明,小鼠B16F10黑色素瘤细胞组成性表达趋化因子受体CXCR3,并且其配体CXCL9/Mig、CXCL10/IP-10和CXCL11/I-TAC在体外可诱导细胞反应,如肌动蛋白聚合、迁移、侵袭和细胞存活。为了确定CXCR3是否在转移至淋巴结(LN)中发挥作用,我们通过反义RNA构建了CXCR3表达降低的B16F10细胞,并在将其皮下接种至同基因宿主C57BL/6小鼠后研究了它们的转移活性。与亲本细胞或空载体转导的细胞相比,这些细胞转移至LN的频率显著降低至约15%(P<0.05)。另一方面,用完全弗氏佐剂预处理小鼠可增加引流LN中CXCL9和CXCL10的水平,这导致B16F10细胞转移至LN的频率增加2.5至3.0倍(P<0.05),且转移灶大得多。重要的是,当通过反义RNA降低B16F10细胞中的CXCR3表达时,或者当用针对CXCL9和CXCL10的特异性抗体处理小鼠时,这种转移刺激在很大程度上受到抑制。我们还证明,CXCR3在几种人黑色素瘤细胞系以及原发性人黑色素瘤组织(9个测试样本中的5个)中表达。这些结果表明,CXCR3抑制剂可能是治疗包括黑色素瘤LN转移在内的有前景的治疗药物。